CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery

 CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery

Shots:

  • CELLINK expand the collaboration for 12 months and will provide bioprinters and bioinks for acceleration of the exploration of novel targets in AstraZeneca’s 5 main therapy areas: oncology, respiratory, and cardiovascular, renal and metabolic diseases
  • The focus of the collaboration is to utilize CELLINK’s portfolio for the creation of seamless workflow from pre-bioprinting preparation of cells to post-bioprinting analysis and will also provide its expertise to work with AZ’s team at their Gaithersburg, US, R&D strategic center
  • AstraZeneca will provide its pharmaceutical development expertise for supporting CELLINK to further refine its offerings in industry. In 2018, CELLINK collaborated with MedImmune to utilize CELLINKs’ 3D-Bioprinting technology for drug discover

Click here to read full press release/ article | Ref: Newscision | Image: Workshop Termis

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post